Ziprasidone in treatment of schizophrenia:a double blind,randomized,controlled,parallel group,and multicenter study

GU Niu-fan
2006-01-01
Abstract:AIM: To evaluate the efficacy and safety of ziprasidone in the treatment of schizophrenia. METHODS: A double blind, double dummy, randomized, controlled, parallel group, and multicenter trial was carried out in ziprasidone and chlorpromazine groups with 120 patients in each. The observation duration was 6 wk. The dose in two groups were initially 60 - 160 mg·d-1 and 250 - 600 mg·d-1 respectively with twice oral adminstrations for wk 2 - 6. PANSS, BPRS and CGI were used as the tools to evaluate the efficacy, while physical examination, lab test, EKG and other adverse events were utilized to evaluate the safety. RESULTS: Two hundred and forty subjects were enrolled with 120 for ziprasidone and clopromazine group respectively. FAS plus SS was 238 patients, including 120 patients in ziprasidone group and 118 patients in clopromazine group. The non-inferior test showed that the efficacy of ziprasidone was not inferior to that of chlopromazine group. The differences of PANSS reduction between the two groups was not significant. The response rates in two groups were 62.5 % vs 58.5 % (P 0.05), respectively. The rates of adverse event and adverse reaction in the two group were 66.7 % vs 66.1 % and 62.5 % vs 63.6 %, respectively. The common adverse events in ziprasidone group were EPS, upper respiratory infection, constipation, insomnia, abnormal ECG, vomiting, somnia, dizziness. CONCLUSION: Ziprasidone is effective and safety in the treatment of schizophrenia. The daily dose range is from 60 mg·d-1 to 160 mg·d-1, po, bid.
What problem does this paper attempt to address?